Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1456-1464

  Curtis, Jeffrey R ^a   Xie, Fenglong ^a   Yun, Huifeng ^a   Saag, Kenneth G ^a   Chen, Lang ^a   Delzell, Elizabeth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DENOSUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; ZOLEDRONIC ACID; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; AGED; ARTHRITIS, RHEUMATOID; COMPLICATION; HOSPITALIZATION; INFECTION; MEDICARE; MIDDLE AGED; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

ABATACEPT; ADALIMUMAB; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; DIPHOSPHONATES; FEMALE; HOSPITALIZATION; HUMANS; IMIDAZOLES; IMMUNOCONJUGATES; INFECTION; INFLIXIMAB; MALE; MEDICARE; MIDDLE AGED; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; UNITED STATES;

EID: 84929925271     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39075     Document Type: Article

References (27)

1. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
2. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, et al., Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 2012; 27: 687-93.
3. Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Torring O, et al., Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011; 96: 1727-36.
4. McClung MR, Boonen S, Torring O, Roux C, Rizzoli R, Bone HG, et al., Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012; 27: 211-8.
5. Dore RK., The RANKL pathway and denosumab. Rheum Dis Clin North Am 2011; 37: 433-52, vi-vii.
6. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al., Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69: 872-5.
7. Watts NB, Roux C, Modlin JF, Brown JP, Daniels A, Jackson S, et al., Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2012; 23: 327-37.
8. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al, for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-9.
9. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al., Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66: 228-34.
10. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
11. Rigby WF, Mease PJ, Olech E, Ashby M, Tole S., Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. J Rheumatol 2013; 40: 599-604.
12. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al, on behalf of the Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-309.
13. Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, et al., Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012; 64: 1480-9.
14. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al., Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 262-70.
15. Curtis JR, Xie F, Chen R, Chen L, Kilgore ML, Lewis JD, et al., Identifying newly approved medications in Medicare claims data: a case study using tocilizumab. Pharmacoepidemiol Drug Saf 2013; 22: 1214-21.
16. Patkar NM, Curtis JR, Teng GG, Allison JJ, Saag M, Martin C, et al., Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol 2009; 62: 321-7.e7.
17. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH., Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol 2007; 60: 397-409.
18. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56: 1125-33.
19. Austin PC., Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simulat Comput 2009; 38: 1228-34.
20. Van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al., Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013; 72: 895-900.
21. Lin D, Wei L, Ying Z., Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 1993; 80: 557-72.
22. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al., Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
23. Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al., Comparative risk of hospitalized infection associated with biological agents among Medicare rheumatoid arthritis patients. Submitted for publication.
24. A study to evaluate the efficacy and safety of denosumab compared with risedronate in individuals taking glucocorticoids (GIOP). URL: http://clinicaltrials.gov/show/NCT01575873.
25. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E., Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) 2012; 64: 1054-60.
26. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896-904.
27. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C., Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56: 4226-7.